Abstract Library

#1105 Pre-PRRT Uptake on 68Ga-DOTATOC Predicts Good Prognosis in Neuroendocrine Tumors Patients

Introduction: There is a growing need to identify PRRT-responders on an early time point during therapy.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Van Binnebeek S

Authors: Van Binnebeek S, Vanbilloen B, Baete K, Bogaerts K, Koole M,

Keywords: PET, response, PRRT,

#335 Dosimetry with 111In-octreotide and Coinfusion of Amino Acids in the Prediction of Nephrotoxicity in Neuroendocrine Tumors after PRRT with 90Y-DOTATOC

Introduction: Kidneys are the critical organs in PRRT. A dosimetry protocol was implemented in an ongoing study to estimate the biological effective dose (BED) on the kidneys after 90Y-DOTATOC therapy.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Van Binnebeek S, Baete K, Vanbilloen B, Terwinghe C, Mottaghy F,

Keywords: PRRT, 90y-DOTATOC, dosimetry, 111in-octreotide, amino acids,

#153 Antibody formation against somatostatin analogues with altered biodistribution and dosimetry: a case with implications for PRRT

Introduction: Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors (NETs) has emerged as a powerful palliative therapy. I.v. administration of radiolabeled (e.g. Yttrium-90) somatostatin analogues (SA) results in high-dose local irradiation of all tumor sites. The radiolabelled SA accumulates in the tumors through receptor-mediated internalization depending on the expression of somatostatin receptors and the pharmacokinetics of the radiolabelled SA.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: VAN BINNEBEEK S

Authors: Van Binnebeek S, DeRoose C, Van Billoen B, Baete K, Mortelmans L,

Keywords: antibody, somatostatin analogue, 90Y-DOTATOC, dosimetry, PRRT, 68Ga-DOTATOC,